Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532125 | 0.89 | L3MBTL4 (0.36) | ALDH1A1CRBNDDB1KMT2AOPRK1 | |
| SCHEMBL30160396 | 0.89 | L3MBTL4 (0.36) | ALDH1A1CRBNDDB1KMT2AOPRK1 | |
| SCHEMBL13800024 | 0.88 | TRPV1 (0.35) | ALDH1A1LMNATP53HTTTSHR | |
| SCHEMBL30160267 | 0.87 | SMYD3 (0.34) | ALDH1A1CRBNDDB1FNTAFNTB | |
| SCHEMBL23532161 | 0.87 | SMYD3 (0.34) | ALDH1A1CRBNDDB1FNTAFNTB | |
| SCHEMBL23532122 | 0.86 | CRBN (0.31) | CRBNDDB1 | |
| SCHEMBL25704837 | 0.86 | TSHR (0.38) | ALDH1A1HTTTSHRCRBNPIK3CD | |
| SCHEMBL23532172 | 0.85 | CRBN (0.33) | CRBNDDB1 | |
| SCHEMBL23532080 | 0.84 | CRBN (0.32) | CRBNDDB1AKR1B1 | |
| SCHEMBL25198512 | 0.83 | FAAH (0.36) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | ALDH1A1 1885/4885LMNA 415/4885TP53 2062/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | ALDH1A1 1859/4885LMNA 281/4885TP53 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.